SCHEMBL397873

SCHEMBL397873

O=[N+]([O-])c1ccccc1C(O)=S

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.58
CTSD P07339 1/20 0.55
TDP1 Q9NUW8 3/20 0.54
ALPL P05186 2/20 0.54
GAA P10253 3/20 0.53
HPGD P15428 2/20 0.53
KDM4E B2RXH2 2/20 0.53
MAPT P10636 2/20 0.53
HTT P42858 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
TSHR P16473 1/20 0.50
GPR35 Q9HC97 2/20 0.48
ALPI P09923 1/20 0.48
ALPG P10696 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL397874 1.00 ALDH1A1 (0.58) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL4252583 0.82 GPR35 (0.56) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL4252579 0.82 GPR35 (0.56) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL28958222 0.82 ALDH1A1 (0.56) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL6142099 0.82 ALDH1A1 (0.56) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL1206488 0.82 CTSD (0.58) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL30727560 0.81 TSHR (0.67) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL29696138 0.81 TSHR (0.67) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL78205 0.81 TSHR (0.67) ALDH1A1CTSDTDP1ALPLGAA
SCHEMBL4078013 0.80 ALDH1A1 (0.64) ALDH1A1CTSDTDP1ALPLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115403791-B Universal method for preparing high molecular nano particles 山东大学 2025-02-25 CN claimed
US-6743598-B2 SIMULTANEOUSLY ASSESSING MICROBIAL PHOSPHOGLUCOSE ISOMERASE, KETOL-ISOMERASE AND GLUCOSAMINE-6-PHOSPHATE ACETYLTRANSFERASE ACTIVITIES MYCOLOGICS, INC. 2004-06-01 US claimed
US-20030194758-A1 Methods for the identification of fungal glucose utilization inhibitors and antifungal agents MYCOLOGICS, INC. 2003-10-16 US claimed
US-20030087877-A1 Modification of biopolymers for improved drug delivery CENZYME CORPORATION 2003-05-08 US claimed
EP-1263472-A2 MODIFICATION OF BIOPOLYMERS FOR IMPROVED DRUG DELIVERY GENZYME CORPORATION (US) 2002-12-11 EP claimed
WO-2001060412-A2 MODIFICATION OF BIOPOLYMERS FOR IMPROVED DRUG DELIVERY GENZYME CORPORATION (US) 2001-08-23 WO claimed
CN-115403791-B Universal method for preparing high molecular nano particles 山东大学 2025-02-25 CN disclosed
US-11980669-B2 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation PFIZER, INC. (US) 2024-05-14 US disclosed
CN-117607133-A Aromatic amine N-acetyltransferase activity detection kit and application thereof 南方海洋科学与工程广东省实验室(广州) 2024-02-27 CN disclosed
CN-117607133-A Aromatic amine N-acetyltransferase activity detection kit and application thereof 南方海洋科学与工程广东省实验室(广州) 2024-02-27 CN disclosed
CN-107849121-B Blocked and unblocked antibody cysteines and their use in antibody-drug conjugation 辉瑞公司 2021-11-09 CN disclosed
EP-3808768-A1 CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION Pfizer Inc. (US) 2021-04-21 EP disclosed
EP-3334760-B1 CAPPED AND UNCAPPED ANTIBODY CYSTEINES, AND THEIR USE IN ANTIBODY-DRUG CONJUGATION PFIZER (US) 2021-03-10 EP disclosed
EP-0083975-B1 HERBICIDAL SULFONAMIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1987-11-19 EP disclosed
US-4695311-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1987-09-22 US disclosed
US-4615877-A Method of determining the oxidizing activity of a biological liquid, and a corresponding reagent SAVAPA S.R.L. (IT) 1986-10-07 US disclosed
US-4606755-A Herbicidal sulfonamides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1986-08-19 US disclosed
US-4511392-A N--/PYRIMIDIN-2-YLAMINOCARBENYL/-HETERO-SUBSTITUETED BENZENSESULFO E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-16 US disclosed
EP-0083975-A2 Herbicidal sulfonamides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-07-20 EP disclosed
EP-0034883-A1 2-Nitro-5-(substituted-phenoxy) benzoyl derivatives as herbicides RHONE-POULENC INC. (US) 1981-09-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11980669-B2 Capped and uncapped antibody cysteines, and their use in antibody-drug conjugation GCLC, LANCL1, CTH ALDH1A1 459/4885CTSD 2390/4885TDP1 4390/4885
US-20030087877-A1 Modification of biopolymers for improved drug delivery PTMS, PDIA6, SDCBP ALDH1A1 1420/4885CTSD 1899/4885TDP1 2775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.